Folia Biologica
Journal of Cellular and Molecular Biology, Charles University 

Crossref logo

Fol. Biol. 2004, 50, 175-183

https://doi.org/10.14712/fb2004050060175

Allogeneic Gene-Modified Tumour Cells in Metastatic Kidney Cancer. Report II

Giancarlo Pizza1, C. De Vinci1, G. Lo Conte1, A. Mazzuca1, V. Di Maio1, S. Ratini1, G. Severini1, L. Busutti2, A. P. Palareti3, A. Gulino4, A. Vacca4, L. Melchiorri5, M. Ferrari6, L. Giacomelli7, O. R. Baricordi5, S. Forzini8, R. Capanna8

1Immunotherapy Module, Operative Unit (O. U.) of Urology, Department of Urology and Nephrology, S. Orsola-Malpighi Hospital, Bologna, Italy
2O.U. of Radiotherapy, Department of Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy
3Department of Computer Science, University of Bologna, Bologna, Italy
4Experimental Medicine, University "La Sapienza", Rome, Italy
5Department of Experimental and Diagnostic Medicine, Section of Medical Genetics, University of Ferrara, Ferrara, Italy
6Experimental Institute of Zooprophylaxis, Emilia-Romagna and Lombardia Regions, Brescia, Italy
7Department of Surgical Science University of Rome "La Sapienza", Rome, Italy
82nd Division of Orthopaedics and Reconstructive Surgery Centre, Florence, Italy

Received November 2004
Accepted November 2004

References

1. ATCC Collection, CRL-1611.
2. Belldegrun, A., Tso, C. L., Sakata, T., Duckett, T., Brunda, M. J., Barsky, S. H., Chai, J., Kaboo, R., Lavey, R. S., McBride, W. H., et al. (1993) Human renal carcinoma line transfected with interleukin-2 and/or interferon alfa gene(s): Implications for live cancer vaccines. J. Natl. Canc. Inst. 85, 207-216. <https://doi.org/10.1093/jnci/85.3.207>
3. Brouwenstijn, N., Hoogstraten, C., Verdegaal, E. M., Van der Spek, C. W., Deckers, J. G., Mulder, A., Osanto, S., Schrier, P. I. (1998) Definition of unique and shared T-cell defined tumour antigens in human renal cell carcinoma. J. Immunother. 21, 427-34. <https://doi.org/10.1097/00002371-199811000-00004>
4. Bukowski, R. M. (1997) Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin-2. Cancer 80, 1198-1220. <https://doi.org/10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H>
5. Bukowski, R. M. (2000) Role of immunotherapy in renal cell carcinoma. Medscape Oncology. (http://www.medscape.com/Medscape/oncology/journal/2000/v03.n01/mo5103.buko/mo5103.buko-01.html/)
6. Cavallo, F., Di Pierro, F., Giovarelli, M., Gulino, A., Vacca, A., Stoppacciaro, A., Forni, M., Modesti, A., Forni, G. (1993) Protective and curative potential of vaccination with IL2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res. 53, 5067-5070.
7. Dillman, R. O., Barth, N. M., VanderMolen, L. A., Garfield, D. H., De Leon, C., OíConnor, A. A., Mandavi, K., Nayak, S. K. (2001) Treatment of kidney cancer with autologous tumour cell vaccines of short-term cell lines derived from renal cell carcinoma. Cancer Biother. Radiopharm. 16, 47-54.
8. Elson, P. J., Witte, R., Trump, D. (1988) Prognostic factors in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 48, 7310-7313.
9. Gillis, S., Watson, J. (1981) Interleukin-2 dependent culture of cytolytic T-cell lines. Immunol. Rev. 54, 81-109. <https://doi.org/10.1111/j.1600-065X.1981.tb00435.x>
10. Graham, F. L., van der Erb, A. J. (1973) A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52, 456-467. <https://doi.org/10.1016/0042-6822(73)90341-3>
11. Hrushsky, W. J., Murphy, G. P. (1977) Current status of therapy of advanced renal cell carcinoma. J. Surg. Oncol. 9, 277-281. <https://doi.org/10.1002/jso.2930090310>
12. Kalbfeisch, J. D., Prentice, R. L. (1980) The Statistical Analysis of Failure Time Data. John Wiley & Sons, Inc., New York.
13. Kaplan, E. L., Meier, P. (1985) Non-parametric estimation from incomplete observations. J. Am. Stat. Ass. 53, 457-481. <https://doi.org/10.1080/01621459.1958.10501452>
14. Oosterwijk, E. E., Ruiter, D. J., Hoedemaeker, P. J., Pauwels, E. K., Jonas, U., Zwartendijk, J., Warnaar, S. O. (1986) Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer 38, 489-494. <https://doi.org/10.1002/ijc.2910380406>
15. Pizza, G., Viza, D., Fini, M., Cuzzocrea, D. E., Menniti, D., Corrado, F. (1980) Transitional cell carcinoma of the bladder. Differences between primary tumour and following relapses. Eur. Urol. 6, 45-47. <https://doi.org/10.1159/000473286>
16. Pizza, G., Severini, G., Menniti, D., De Vinci, C., Corrado, F. (1984) Tumour regression after intralesional injection of interleukin-2 (IL2) in bladder cancer: preliminary report. Int. J. Cancer 34, 359-367. <https://doi.org/10.1002/ijc.2910340312>
17. Pizza, G., De Vinci, C., Aiello, A., Corrado, G., Lo Conte, G., Mazzuca, A., Baricordi, O. R.,Vacca, A., Gulino, A., Fornarola, V., Capanna, R., Busutti, L. (1999) Gene immunotherapy in metastatic renal cell cancer (MRCC) using allogeneic tumour-cell line engineered with the human gene of interleukin-2 (IL2) and autologous formalin-fixed tumour cells: preliminary results in one patient. Urologia 66, S18-S21. (in Italian)
18. Pizza, G., De Vinci, C., Lo Conte, G., Maver, P., Dragoni, E., Aiello, E., Fornarola, V., Bergami, T., Busutti, L., Boriani, S., Palareti, A. P., Capanna, R. (2001) Immunotherapy of metastatic kidney cancer. Int. J. Cancer 94, 109-120. <https://doi.org/10.1002/ijc.1426>
19. Pizza, G., De Vinci, C., Viza, D. (2002) Immunotherapeutic approaches for renal cancer. Folia Biol. (Praha) 48, 167-181.
20. Pizza, G., De Vinci, C., Lo Conte, G., Mazzuca, A., Corrado, G., Menniti, D., Benati, A., Romagnoli, P., Fornarola, V., Busutti, L., Palareti, A. P., Capanna, R., Di Maio, V., Ratini, S., Gulino, A., Vacca, A., Melchiorri, L., Ferrari, M., Boriani, S., Baricordi. R. O. (2003) Allogeneic genemodified tumour cells in metastatic kidney cancer. Preliminary report. Folia Biol. (Praha) 49, 147-159.
21. Schwaab, T., Heaney, J. A., Schned, A. R., Harris, R. D., Cole, B. F., Noelle, R. J., Phillips, D. M., Stempkowski, L., Ernstoff, M. S. (2000) A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha 2b therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J. Urol. 163, 1322-1327. <https://doi.org/10.1016/S0022-5347(05)67771-3>
22. Ueda, R., Ogata, S., Morrissey, D. M., Finstad, C. L., Szkudlarek, J., Whitmore, W. F., Oettgen, H. F., Lloyd, K. O., Old, L. J. (1981) Cell surface antigens: serological analysis of human renal cancer defined by mouse monoclonal antibodies: identification of tissue specific glycoproteins. Proc. Natl. Acad. Sci. USA 78, 5122-5126. <https://doi.org/10.1073/pnas.78.8.5122>
23. Vogelzang, N. J., Stadler, W. M. (1998) Kidney cancer. Lancet 352, 1691-1696. <https://doi.org/10.1016/S0140-6736(98)01041-1>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive